antidiabetic glp 1 Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management Perioperative Considerations of Novel Antidiabetic

Injectable semaglutide (Wegovy, Ozempic): Subcutaneous injection delivers drug directly into tissue Slow absorption from injection site into bloodstream Terminal half-life: 165 to 184 hours (approximately 7 days) Steady state reached after 4 to 5 weeks of weekly dosing Weekly dosing works because each injection adds to existing blood levels before previous dose is fully eliminated Oral semaglutide (Rybelsus): Absorption occurs in stomach via SNAC-mediated mechanism Peak plasma concentration at 1 hour Rapid distribution phase (1 to 6 hours) Terminal half-life is the same (7 days) once the drug is in the bloodstream, but the absorption phase is completely different Daily dosing is required because the absorption event itself is daily, not because the elimination is fast The confusion arises because half-life describes elimination, not absorption

The question is not if this will happen

Both work fine alongside GHK-Cu when separated

See Also: Complete CJC-1295 Research Guide

The three potentially blinding eye conditions included NAION, papillitis, and paracentral acute middle maculopathy